BridgeBio Pharma (NASDAQ:BBIO) Trading 9.3% Higher Following Analyst Upgrade

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) traded up 9.3% during trading on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $89.00 to $94.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. BridgeBio Pharma traded as high as $70.49 and last traded at $71.7590. 1,265,413 shares were traded during mid-day trading, a decline of 60% from the average session volume of 3,135,348 shares. The stock had previously closed at $65.64.

A number of other equities analysts have also commented on the stock. Oppenheimer decreased their price target on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Truist Financial raised their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Barclays started coverage on BridgeBio Pharma in a research note on Wednesday, January 28th. They set an “overweight” rating for the company. Finally, Morgan Stanley increased their price objective on BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $83.35.

Insiders Place Their Bets

In related news, CAO Maricel Apuli sold 510 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total transaction of $37,898.10. Following the transaction, the chief accounting officer owned 123,945 shares in the company, valued at $9,210,352.95. This represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Randal W. Scott sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total transaction of $754,600.00. Following the sale, the director directly owned 11,589 shares of the company’s stock, valued at approximately $874,505.94. The trade was a 46.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 227,095 shares of company stock worth $16,099,240. 18.20% of the stock is owned by corporate insiders.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Phase‑3 FORTIFY interim analysis shows early and durable benefit for BBP‑418 (improved ambulation with separation from placebo as early as 3 months, 31‑second improvement on 100MTT at 12 months), CK reductions, and a favorable safety profile; BridgeBio plans an NDA submission in H1 2026 and targets a U.S. launch in late‑2026/early‑2027. BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile
• Positive Sentiment: Media coverage highlights BBP‑418 as a potential first‑in‑class therapy for a rare, unmet disease (LGMD2I/R9), increasing visibility among rare‑disease investors and specialty funds. BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder
• Positive Sentiment: Broker support: JPMorgan raised its price target (to $94, Overweight) and William Blair initiated coverage with an Outperform — these actions broaden buyer interest and lift consensus upside. JPMorgan Raises Price Target
• Positive Sentiment: Institutional accumulation noted in recent filings (large additions from T. Rowe, Janus, Wellington in Q4’25) — signals lasting investor conviction beyond short‑term moves. Quiver Quant — FORTIFY Results and Institutional Activity
• Neutral Sentiment: HC Wainwright updated multi‑year estimates and keeps a Buy/$100 target but tweaked near‑term EPS (mixed revisions — some quarters lowered, later quarters showing profitability). This reinforces long‑term upside while acknowledging near‑term variability. HC Wainwright Estimate Note
• Neutral Sentiment: Management presentations and conference transcripts (Barclays, MDA) provide additional data/context but are informational rather than new clinical events. Barclays Conference Transcript
• Neutral Sentiment: Reported short‑interest figures in the feeds appear to be erroneous (zero/NaN entries) — treat those data points with caution.
• Negative Sentiment: Significant insider selling reported over the past 6 months (CEO and other executives have sold material share blocks), which can concern some investors about timing or liquidity needs despite company progress. Quiver Quant — Insider Trading Summary

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC bought a new position in BridgeBio Pharma during the second quarter valued at $643,000. WINTON GROUP Ltd purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at approximately $3,856,000. Principal Financial Group Inc. grew its stake in BridgeBio Pharma by 23.0% in the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after purchasing an additional 236,885 shares in the last quarter. L & S Advisors Inc purchased a new position in BridgeBio Pharma during the 3rd quarter worth $877,000. Finally, Federated Hermes Inc. raised its position in BridgeBio Pharma by 53.0% during the 3rd quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock valued at $22,059,000 after purchasing an additional 147,108 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Stock Performance

The firm has a market capitalization of $13.47 billion, a PE ratio of -18.30 and a beta of 1.13. The company has a fifty day simple moving average of $73.32 and a two-hundred day simple moving average of $65.78.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analysts’ expectations of $150.71 million. During the same period in the previous year, the company posted ($1.40) EPS. The company’s revenue was up 2521.2% on a year-over-year basis. On average, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.